Loading viewer...
earnings
Format: PDF earnings
Halozyme Therapeutics presents Q3 2016 earnings results and updates on its HALO-301 Phase 3 trial investigating PEGPH20 combined with ABRAXANE and gemcitabine for metastatic pancreatic cancer. The randomized, double-blind study enrolls approximately 420 patients across 200 sites in 20 countries with progression-free survival and overall survival as primary endpoints.
investor_presentation
31 Pages
earnings
16 Pages
Unknown
Fortress Investment Group Q3 2016 Earnings Supplement
earningsearnings
22 Pages
Fortress Investment Group
KapStone Paper 2016 Q2 Financial Review
earningsearnings
15 Pages
KapStone Paper and Packaging
VIZIO Q4 2023 Earnings Call Results
earningsearnings
19 Pages
VIZIO Holding Corp